LCM
ACER

Laurion Capital Management’s Acer Therapeutics Inc ACER Stock Holding History

Laurion Capital Management’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,400
Closed -$253K – 1247
2019
Q1 		$253K Buy
+10,400
New +$245K ﹤0.01% 728

Other funds holding ACER

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Laurion Capital Management's ACER Position: Q2 2019 in Review

Laurion Capital Management sold out of Acer Therapeutics Inc (ACER) in Q2 2019, closing a stake of 10,400 shares — an estimated $253K sold.

Laurion Capital Management first reported a position in ACER in Q1 2019 and held it in 1 quarter. The position peaked at $253K in Q1 2019. 37 funds tracked by Wall St. Rank hold ACER as of Q2 2019.

  • Laurion Capital Management reported no remaining Acer Therapeutics Inc position as of Q2 2019 after selling out during the quarter.
  • Laurion Capital Management sold 10,400 Acer Therapeutics Inc shares in Q2 2019, an estimated $253K.
  • Laurion Capital Management first reported a position in Acer Therapeutics Inc in Q1 2019 and held it in 1 quarter.
  • Laurion Capital Management's Acer Therapeutics Inc position peaked at $253K in Q1 2019.
  • 37 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q2 2019.

Based on Laurion Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.